[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362814-105":59,"doc-detail-362814-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","incidence-and-management-of-pyrexia-syndrome-in-patients-treated-with-dabrafenib-and-trametinib-a-retrospective-study","Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study","","Combination dabrafenib and trametinib is widely used for BRAF-mutant cancers, with pyrexia syndrome as the most common adverse effect. This retrospective cohort study evaluated the incidence of pyrexia syndrome and severe/complicated cases, and assessed clinical outcomes and management strategies. Patients receiving dabrafenib and trametinib from 2015 to 2022 were identified from a large academic medical center, using chart review to capture onset, severity, treatment duration, and discontinuation reasons.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/incidence-and-management-of-pyrexia-syndrome-in-patients-treated-with-dabrafenib-and-trametinib-a-retrospective-study/362814/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/incidence-and-management-of-pyrexia-syndrome-in-patients-treated-with-dabrafenib-and-trametinib-a-retrospective-study/362814.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main adverse effect examined in patients treated with dabrafenib and trametinib?","Question",{"text":112,"@type":113},"The study focuses on pyrexia syndrome, the most common adverse effect associated with this combination.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was pyrexia syndrome incidence determined in this retrospective study?",{"text":117,"@type":113},"Researchers identified patients treated from 2015 to 2022 and performed chart review to determine whether patients developed pyrexia syndrome, its severity, onset timing, and related outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What management strategies were used for pyrexia syndrome in this cohort?",{"text":121,"@type":113},"Pyrexia syndrome was managed using dose modifications and interruptions, along with agents including steroids, antipyretics, and colchicine.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362814,1790272219,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Supportive Care in Cancer (2026) 34:385  \n[https://doi.org/10.1007/s00520-026-10624-y](https://doi.org/10.1007/s00520-026-10624-y)  \nIncidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study  \nJustin Komisarof1 · Jayesh Menon2 · Aryn Andrzejewski2 · Deborah Mulford2  \nReceived: 13 November 2025 / Accepted: 25 March 2026 / Published online: 29 March 2026 © The Author(s) 2026  \nAbstract  \nPurpose The combination of dabrafenib and trametinib has been used to treat a variety of cancers featuring BRAF mutations. The most common adverse effect is pyrexia syndrome. We aimed to determine the incidence of pyrexia syndrome and severe/ complicated pyrexia syndrome and investigate outcomes associated with pyrexia syndrome as well as pyrexia management. Methods In this retrospective cohort study, individuals who received dabrafenib and trametinib from 2015 to 2022 at a large academic medical center were identified. Chart review was performed to determine if patients developed pyrexia syndrome, the severity of pyrexia syndrome, time of onset of pyrexia, time on treatment, how pyrexia was managed, and why treatment was discontinued.  \nResults 88 patients were included in the final analysis. 34 patients (38.6%) developed pyrexia syndrome and 14 patients (15.9%) developed severe/complicated pyrexia syndrome. Most patients who developed pyrexia syndrome did so in their first month of treatment. Patients who developed pyrexia syndrome were more likely to discontinue treatment due to an adverse event than patients who did not (32.3% vs 22.2%). Patients who developed pyrexia syndrome spent a longer mean period on treatment (16.9 months) than patients who did not (9.0 months) . Pyrexia syndrome was managed with dose modificationsand interruptions and several agents including steroids, antipyretics, and colchicine.  \nConclusion Pyrexia syndrome is a common adverse event in patients on dabrafenib and trametinib. Patients who develop pyrexia syndrome unexpectedly stayed on treatment longer in our cohort, highlighting the importance of early recognition and supportive management to maintain patients on therapy.  \nKeywords Pyrexia · Severe/complicated pyrexia · BRAFV600E · Targeted therapy · Dabrafenib and trametinib  \nIntroduction  \nThe combination of dabrafenib and trametinib has been used to treat a variety of malignancies featuring BRAFV600E and V600K mutations, most frequently melanoma [1 , 2] . The most common adverse effect in patients on dabrafenib/trametinib is pyrexia syndrome, which occurs in approximately 50% of melanoma patients in the metastatic setting, and approximately 60% of melanoma patients in the adjuvant setting [3, 4] . Pyrexia syndrome is defined by the Canadian Working Group as fever > 38 °C and/or  \n* Justin Komisarof [Justin.komisarof@bcm.edu](Justin.komisarof@bcm.edu)  \n1 Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA  \n2 University of Rochester Medical Center, Rochester, NY, USA  \nchills, rigors, and night sweats ± flu-like symptoms [4] . The working group further defined severe/complicated pyrexia as pyrexia syndrome requiring hospitalization, or pyrexia complicated by Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher dehydration, hypotension, renal dysfunction, confusion, or vomiting [4] . While pyrexia syndrome is seen most frequently with dabrafenib/ trametinib, it is also seen in approximately 20% of patients on other BRAF/MEK inhibitor combinations such as vemurafenib/cobimetinib and encorafenib/binimetinib, suggesting that pyrexia syndrome is caused by the effect of signaling pathway blockade rather than an individual targeted therapy agent [3, 5, 6] . Pyrexia syndrome secondary to dabrafenib/ trametinib is not specific to any single cancer, occurring in approximately 50% of patients with non-small-cell lung cancer (NSCLC) and 37% of patients with anaplastic thyroid cancer [7, 8] .  \nPyrexia syndrome is usually tr","cbCaipHQfuiYZCZ3","https://ap.wps.com/l/cbCaipHQfuiYZCZ3","pdf",669791,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Study design\n## Participants\n## Procedures/outcomes","[{\"question\":\"What is the main adverse effect examined in patients treated with dabrafenib and trametinib?\",\"answer\":\"The study focuses on pyrexia syndrome, the most common adverse effect associated with this combination.\"},{\"question\":\"How was pyrexia syndrome incidence determined in this retrospective study?\",\"answer\":\"Researchers identified patients treated from 2015 to 2022 and performed chart review to determine whether patients developed pyrexia syndrome, its severity, onset timing, and related outcomes.\"},{\"question\":\"What management strategies were used for pyrexia syndrome in this cohort?\",\"answer\":\"Pyrexia syndrome was managed using dose modifications and interruptions, along with agents including steroids, antipyretics, and colchicine.\"}]","Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study | PDF",1790149138,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/180ae93dbe1f86935777496c2256ec86.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd41abc92c425a487ac179f9594d2426.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fd4fb21710b072c9679a77d095be2d1.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d4828cc87b69789eed19c8c02aa74d0.webp",980,1301]